GeneDx Corp. (WGS)
NASDAQ: WGS
· Real-Time Price · USD
129.33
-3.21 (-2.42%)
At close: Sep 08, 2025, 3:59 PM
129.33
0.00%
After-hours: Sep 08, 2025, 06:03 PM EDT
GeneDx Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Diagnostic Test Revenue | 99.82M | 85.76M | 155.3M | 77.42M | 69.44M | 59.34M | 81.49M | 34M | 52.49M |
| Diagnostic Test Revenue Growth | +16.40% | -44.78% | +100.60% | +11.49% | +17.01% | -27.18% | +139.65% | -35.22% | n/a |
| Diagnostic Test, Institutional Customers Revenue | 18.38M | 17.6M | 31M | 17.41M | 16.7M | 15.73M | 15.24M | 11.12M | 4.03M |
| Diagnostic Test, Institutional Customers Revenue Growth | +4.41% | -43.22% | +78.04% | +4.31% | +6.14% | +3.18% | +37.09% | +175.86% | n/a |
| Diagnostic Test, Self Pay Revenue | 339K | 96K | 1.19M | 460K | 692K | 3.24M | 1.85M | 1.49M | 1M |
| Diagnostic Test, Self Pay Revenue Growth | +253.12% | -91.94% | +158.91% | -33.53% | -78.66% | +74.82% | +24.83% | +48.30% | n/a |
| Diagnostic Test, Third Party Insurance Revenue | 81.1M | 68.06M | 123.1M | 59.54M | 52.05M | 40.37M | 64.39M | 21.4M | 47.46M |
| Diagnostic Test, Third Party Insurance Revenue Growth | +19.17% | -44.71% | +106.75% | +14.39% | +28.93% | -37.30% | +200.92% | -54.92% | n/a |
| Product and Service, Other Revenue | 2.87M | 1.36M | 2.76M | -544K | 1.07M | 2M | 1.74M | 2.17M | 1.45M |
| Product and Service, Other Revenue Growth | +111.58% | -50.91% | -607.72% | -150.60% | -46.38% | +14.97% | -19.45% | +49.72% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 46.86M | 50.45M | 45.03M | 43.17M | 41.76M | 39.5M | 38.97M | 42.86M | 52.52M | 57.14M | 72.44M | 89.31M | 104.15M | 72.33M | 88.6M | 55.35M | 29.04M | 137.4M | 91.14M | 37.08M |
| Selling, General, and Administrative Revenue Growth | -7.11% | +12.05% | +4.30% | +3.39% | +5.70% | +1.38% | -9.08% | -18.39% | -8.08% | -21.12% | -18.89% | -14.25% | +43.99% | -18.36% | +60.07% | +90.60% | -78.86% | +50.75% | +145.82% | n/a |
| Research and Development Revenue | 15.08M | 12.58M | 11.59M | 11.66M | 10.69M | 11.57M | 10.03M | 14.29M | 17.14M | 14.59M | 24.37M | 13.35M | 27.17M | 21.32M | 22.25M | 17.83M | 11.95M | 53.13M | 31.16M | 19.08M |
| Research and Development Revenue Growth | +19.89% | +8.53% | -0.66% | +9.11% | -7.57% | +15.34% | -29.81% | -16.63% | +17.45% | -40.11% | +82.46% | -50.85% | +27.46% | -4.19% | +24.76% | +49.16% | -77.50% | +70.52% | +63.29% | n/a |
| Sales and Marketing Revenue | 19.45M | 18.32M | 17.68M | 17.02M | 16.59M | 16.09M | 14.19M | 16.76M | 15.32M | 13.45M | 31.8M | 37.45M | 36.12M | 29.55M | 30.65M | 22.12M | 16.25M | 35.37M | 30.03M | 12.73M |
| Sales and Marketing Revenue Growth | +6.18% | +3.62% | +3.82% | +2.65% | +3.11% | +13.37% | -15.36% | +9.38% | +13.92% | -57.69% | -15.10% | +3.69% | +22.24% | -3.59% | +38.54% | +36.15% | -54.06% | +17.77% | +135.80% | n/a |